Rampurna Prasad Gullapalli, Ph.D., is responsible for providing strategic scientific and technical leadership in areas of softgel, liquid-filled hard capsules, and novel drug delivery technologies. Prior to joining Pii, Dr. Gullapalli served as an Associated Director at Elan Pharmaceuticals from 2006 to 2011, where he was responsible for preformulation and oral dosage form development for several new chemical entities (NCEs). He also served in various scientific positions with increasing responsibilities at Chiron Corporation, Purdue Pharma, Banner Pharmacaps, and R.P. Scherer (currently Catalent). During his career, Dr. Gullapalli has had extensive experience in the development and manufacturing of a broad range of dosage forms including softgels, liquid-filled hard capsules, nanosuspensions, suspensions, solutions, and controlled release tablets and capsules for highly insoluble and soluble compounds.
Dr. Gullapalli holds a B. Pharmacy from Kakatiya University (India), a M. Pharmacy in Pharmacology from Andhra University (India), and a Ph.D. in Pharmaceutics from the University of Tennessee, Memphis (USA). He holds Regulatory Affairs Certification (RAC-US) and is experienced in the FDA and EMA CMC regulatory submissions. Dr. Gullapalli is an invited guest lecturer at the University of California at Davis and authored/co-authored several publications in professional journals and presentations at national conferences. He is also an inventor/co-inventor of several patents and patent applications.